Can BiTEs take a bite out of CAR-Ts in hematologic cancers?
Download a PDF of this article here. Hematologic cancers account for ~10% of annual new cancer diagnoses and continue to have some of the poorest overall outcomes, particularly for older adults. However, the last decade has seen major clinical improvements, led by drugs from two new modalities: cell therapy and bispecifics. Here, we discuss the looming competition between these two drug-classes for hematological cancer indications. With recent approvals, and multiple late-stage assets for the same indication, the success of future launches will depend on how treatment paradigms shift, or do